Últimas noticias sobre DBV Technologies (NASDAQ:DBVT) Bolsa

DBV TECHNOLOGIES SA-SPON ADR

DBV Technologies

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Stock,Market,Graph,Trading,Analysis,Investment,Financial,,Stock,Exchange,Financial

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABSI

ALLT

ALUR

ASNS

AXDX

DBVT

DEVS

FNGR

GRAL

LRHC

LUCY

PLRZ

UBER

WBUY

XHLD

XTKG

Las acciones de Everus Construction Group suben un 14,7 % tras superar expectativas de ganancias y ventas en el primer trimestre.

Acciones de Everus Construction (ECG) se disparan un 15%; Aquí están 20 acciones que se mueven en premercado

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA

DBV TECHNOLOGIES SA by DBV Technologies SA

<h3>Gainers</h3>
<ul>
<li>Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) shares moved upwards by 24.0% to $5.99 during Tuesday's after-market session. The market value of their outstanding shares is at $38.9 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares increased by 18.7% to $3.11. The company's market cap stands at $4.4 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) stock moved upwards by 8.69% to $0.77. The company's market cap stands at $40.4 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock increased by 8.56% to $0.73. The company's market cap stands at $51.4 million. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) shares increased by 6.95% to $0.34. The market value of their outstanding shares is at $11.2 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock moved upwards by 6.45% to $1.65. The company's market cap stands at $2.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares fell 20.5% to $45.03 during Tuesday's after-market session. The market value of their outstanding shares is at $27.0 billion. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares fell 17.14% to $1.7. The company's market cap stands at $4.1 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) stock fell 12.79% to $0.3. The company's market cap stands at $6.6 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares decreased by 9.55% to $0.28. The company's market cap stands at $13.3 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares fell 9.29% to $9.48. The company's market cap stands at $250.5 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares fell 8.09% to $0.25. The market value of their outstanding shares is at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASBP

GNPX

MBIO

MODD

OGEN

PLUR

VERO

12 Health Care Stocks Moving In Tuesday's After-Market Session

JMP Securities analyst Jonathan Wolleben reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and maintains $21 price target.

Price Target

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Outperform on DBV Technologies, Maintains $21 Price Target

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
<ul>
<li>First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal Investigator</li>
<li>Additional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings</li>
</ul>
DBV Technologies (TRQX:<a href="https://www.benzinga.com/stock/DBVp#TRQX">DBVp</a>), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin&#xAE; Peanut patch 250 μg in peanut-allergic children ages 1 – 3 years old.
COMFORT Toddlers will enroll approximately 480 subjects at approximately 80 – 90 study centers across the U.S., Canada, Australia, UK and Europe. Principal Investigator, Jeffrey Leflein, MD, FAAAAI, FACAAI from the Respiratory Medicine Research Institute of Michigan, in Ann Arbor, Michigan screened the first subject in the study. Additionally, Dr. Doug McMahon, MD, Allergy and Asthma Center in Maplewood, Minnesota and Dr. Jason Ohayon, MD, Hamilton Allergy and Immunology Clinic in Ontario, Canada have been activated and are currently open to recruitment.
"I am thrilled that our talented team of clinicians was the first to screen a subject for the COMFORT Toddlers supplemental safety study and we have several other potential subjects scheduled for screening," said Dr. Leflein. "The initiation of subject enrollment in COMFORT Toddlers reinforces our commitment to peanut-allergic children and their families and is an important step in generating the data needed to potentially advance the Viaskin Peanut patch to market."
COMFORT Toddlers is a Phase 3 double-blind, placebo-controlled (DBPC) safety study designed to supplement the safety and efficacy data from the completed Phase 3 EPITOPE study in the same population. The study duration will be six months followed by an optional 18-month open-label treatment phase, to generate up to 24 or 18 months of active treatment with the Viaskin Peanut patch for participants randomized to the active or placebo groups, respectively.
"I am very pleased subject screening has commenced in COMFORT Toddlers and look forward to working with my fellow investigators on the efficient enrollment and execution of this important study,"&nbsp;stated Julie Wang, MD, FAAAAI, FACAAI, Professor of Pediatrics, Jaffe Food Allergy Institute, the Icahn School of Medicine at Mount Sinai and Global Principal Investigator for the COMFORT Toddlers study.&nbsp;"The interest we've seen to date further reinforces the significant unmet need that exists for this specific subject cohort."
"Screening our first subject marks a crucial step forward in our mission to develop this potential groundbreaking therapy for food allergic patients, as we are now well underway with both of our core clinical programs," said Daniel Tassé CEO, DBV Technologies. "We believe the data generated through the COMFORT Toddlers study will complete the data set necessary for a Biologics License Application submission to the FDA. DBV is committed to advancing the development of Viaskin Peanut. Our patients and their families are counting on us."

Biotech

General

DBV Technologies Announces It Has Screened The First Subject In COMFORT Toddlers Supplemental Safety Study In Peanut Allergic Toddlers 1 – 3 Years Old

DBV Technologies To Present New Clinical Data On VIASKIN Peanut And Cow's Milk Allergy Patches At EAACI 2025 Congress

Goldman Sachs analyst Rajan Sharma reinstates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Sell and announces $7.25 price target.

Initiation

Goldman Sachs Reinstates Sell on DBV Technologies, Announces $7.25 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Ascendiant Capital raised Pro-Dex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) price target from $54 to $56. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Pro-Dex shares closed at $46.24 on Friday. <a href="https://www.benzinga.com/quote/PDEX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. slashed the price target for Unity Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) from $4 to $2. HC Wainwright &amp; Co. analyst Matthew Caufield downgraded the stock from Buy to Neutral. Unity Biotechnology shares closed at $0.7790 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/UBX/analyst-ratings">view this stock</a>.</li>
<li>JMP Securities cut Churchill Downs Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) price target from $144 to $138. JMP Securities analyst Jordan Bender maintained a Market Outperform rating. Churchill Downs shares closed at $93.24 on Friday. See how other <a href="https://www.benzinga.com/quote/CHDN/analyst-ratings">analysts view this stock</a>.</li>
<li>JMP Securities increased the price target for DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) from $15 to $21. JMP Securities analyst Jonathan Wolleben maintained a Market Outperform rating. DBV Technologies shares closed at $8.41 on Friday. <a href="https://www.benzinga.com/quote/DBVT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group increased the price target for Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from $85 to $100. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar General shares closed at $101.39 on Friday. See how other <a href="https://www.benzinga.com/quote/DG/analyst-ratings">analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) price target from $30 to $14. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Prothena shares settled at $6.58 on Friday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group increased Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $82 to $95. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar Tree shares closed at $88.17 on Friday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim cut Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) price target from $155 to $115. Guggenheim analyst Robert Drbul maintained a Buy rating. Target shares closed at $94.29 on Friday.  <a href="https://www.benzinga.com/quote/TGT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Chardan Capital cut the price target for Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from $40 to $18. Chardan Capital analyst Rudy Li maintained a Buy rating. Prothena shares settled at $6.58 on Friday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) price target from $68 to $74. Wells Fargo analyst Tiago Fauth maintained an Overweight rating. PTC Therapeutics shares closed at $45.93 on Friday. <a href="https://www.benzinga.com/quote/PTCT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying PTCT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-1024x582.png" alt="" class="wp-image-928475" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dick&#8217;s Sporting Goods Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

CHDN

DLTR

PDEX

PRTA

PTCT

PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday

WIIM

DBV Technologies shares are trading higher after JMP Securities raised its price target on the stock from $15 to $21 and maintained an Outperform rating.

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock increased by 88.9% to $0.76 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) stock rose 34.55% to $0.88. The market value of their outstanding shares is at $35.4 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) stock moved upwards by 15.2% to $11.32. The market value of their outstanding shares is at $236.6 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock rose 11.47% to $1.35. The company's market cap stands at $88.8 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares moved upwards by 11.41% to $9.37. The market value of their outstanding shares is at $256.2 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares moved upwards by 11.25% to $4.44. The company's market cap stands at $292.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) stock decreased by 62.5% to $2.35 during Tuesday's pre-market session. The company's market cap stands at $253.1 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares decreased by 31.03% to $0.8. The market value of their outstanding shares is at $14.0 million. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) stock decreased by 26.9% to $4.81. The market value of their outstanding shares is at $258.9 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 20.15% to $447.17. The company's market cap stands at $5.8 billion. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares decreased by 13.07% to $4.59. The company's market cap stands at $125.2 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock declined by 10.97% to $0.21. The company's market cap stands at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRNS

BSGM

IMNN

IOBT

NVCT

RCKT

STIM

VTAK

WORX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

JMP Securities analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and raises the price target from $15 to $21.

JMP Securities Maintains Market Outperform on DBV Technologies, Raises Price Target to $21

<h3>Gainers</h3>
<ul>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock moved upwards by 2412.3% to $5.12 during Tuesday's regular session. The company's market cap stands at $466.1 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 42.47% to $1.61. The company's market cap stands at $4.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock moved upwards by 23.28% to $0.28. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 22.5% to $431.22. The market value of their outstanding shares is at $5.6 billion. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) stock rose 18.79% to $1.68. The market value of their outstanding shares is at $307.3 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares increased by 17.2% to $1.35. The company's market cap stands at $53.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 31.1% to $7.65 during Tuesday's regular session. The market value of their outstanding shares is at $4.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares decreased by 17.74% to $8.88. The company's market cap stands at $243.0 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) shares fell 15.14% to $0.28. The company's market cap stands at $8.1 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares decreased by 13.64% to $0.01. </li>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares declined by 12.62% to $7.38. The company's market cap stands at $629.6 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 11.85% to $5.25. The company's market cap stands at $285.3 million. The company's, Q1 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

AVXL

BIAF

EKSO

EYEN

PTIX

TELA

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Septerna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) stock rose 74.9% to $11.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $523.9 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares rose 63.63% to $3.24. The market value of their outstanding shares is at $9.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock moved upwards by 51.72% to $9.65. The market value of their outstanding shares is at $198.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares increased by 14.34% to $144.0. The market value of their outstanding shares is at $782.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock moved upwards by 14.01% to $12.53. The company's market cap stands at $342.7 million. </li>
<li>Advanced Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVB#NASDAQ">ADVB</a>) shares increased by 12.74% to $1.15. The company's market cap stands at $24.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock fell 46.3% to $0.02 during Wednesday's pre-market session. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares decreased by 29.44% to $0.06. The company's market cap stands at $1.5 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock decreased by 16.79% to $0.17. The market value of their outstanding shares is at $8.9 million. </li>
<li>EUDA Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EUDA#NASDAQ">EUDA</a>) shares decreased by 15.48% to $3.55. The company's market cap stands at $131.8 million. </li>
<li>GRAIL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) stock fell 13.15% to $37.25. The market value of their outstanding shares is at $1.3 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) shares fell 12.03% to $1.39. The market value of their outstanding shares is at $52.5 million. As per the press release, Q1 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVB

APYX

Euda Health Holdings Limited - Ordinary Shares

EUDA

NUTX

QNRX

SEPN

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Shares of Everus Construction Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) rose sharply in today's pre-market trading after the company<a href="https://www.benzinga.com/quote/ECG"> posted better-than-expected first-quarter results.</a>
Everus Construction Group reported quarterly earnings of 72 cents per share which beat the analyst consensus estimate of 43 cents per share. The company reported quarterly sales of $826.63 million which beat the analyst consensus estimate of $676.35 million.
Everus Construction shares jumped 14.7% to $59.00 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) rose 84.2% to $2.21 in pre-market trading after gaining 4% on Tuesday.</li>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) surged 54.1% to $3.05 in pre-market trading as the company posted a narrower-than-expected quarterly loss.</li>
<li>La Rosa Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) gained 40.2% to $0.1963 in pre-market trading.</li>
<li>Allurion Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NASDAQ">ALUR</a>) jumped 31% to $3.09 in pre-market trading.</li>
<li>DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) gained 30.2% to $0.7422 in pre-market trading after the company signed a MoU with Fayafi Investment Holding to explore creation of &#8220;Fayafi x DevvStream Green Ventures.&#8221;</li>
<li>WEBUY GLOBAL LTD. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) surged 21.9% to $8.84 in pre-market trading after dipping more than 18% on Tuesday.</li>
<li>FingerMotion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNGR#NASDAQ">FNGR</a>) climbed 16.4% to $5.10 in pre-market trading after gaining 24% on Tuesday.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) gained 16.3% to $12.78 in pre-market after gaining 8% on Tuesday.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) gained 13.9% to $3.37 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 44.2% to $0.0159 in pre-market trading after dipping 92% on Tuesday.</li>
<li>TEN Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) fell 35.3% to $0.89 in pre-market trading after jumping 112% on Tuesday.</li>
<li>Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) fell 33% to $0.0590 in today's pre-market trading after tumbling 34% on Tuesday.</li>
<li>X3 Holdings Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) shares dipped 24.2% to $1.60 in pre-market trading after gaining 88% on Tuesday.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) fell 21.3% to $0.63 in pre-market trading after posting weak quarterly sales.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) shares fell 16.7% to $6.11 in pre-market trading after Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) announced plans to sell some of its Aurora Innovation stake in a senior notes offering.</li>
<li>Abpro Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) dipped 16.2% to $0.1719 in pre-market trading.</li>
<li>GRAIL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) shares tumbled 14.1% to $36.86 in pre-market trading after reporting weak quarterly sales.</li>
<li>American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) declined 13.8% to $10.96 in pre-market trading after the company guided first-quarter revenue down and withdrew FY25 guidance.</li>
<li>Allot Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) fell 8.1% to $7.79 in pre-market trading after gaining 8% on Tuesday.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Why Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

HC Wainwright &amp; Co. analyst Andrew Fein maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Buy and raises the price target from $7 to $16.

HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $16

JMP Securities analyst Steven Delaney maintains DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and raises the price target from $10 to $15.

JMP Securities Maintains Market Outperform on DBV Technologies, Raises Price Target to $15

DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) reported quarterly losses of $(0.26) per share. This is a 7.14 percent increase over losses of $(0.28) per share from the same period last year.

Earnings

DBV Technologies Q1 EPS $(0.26) Up From $(0.28) YoY

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 40.8% to $1.32 during Monday's after-market session. The market value of their outstanding shares is at $231.0 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock increased by 8.77% to $0.77. The market value of their outstanding shares is at $61.6 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock rose 8.29% to $2.48. The market value of their outstanding shares is at $6.1 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 7.9% to $0.09. The company's market cap stands at $1.3 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares moved upwards by 6.55% to $0.3. The market value of their outstanding shares is at $4.2 million. </li>
<li>Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) stock increased by 6.16% to $3.79. The market value of their outstanding shares is at $188.9 million. The company's, FY earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares declined by 12.6% to $8.37 during Monday's after-market session. The company's market cap stands at $712.2 million. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares decreased by 10.38% to $3.8. The market value of their outstanding shares is at $170.1 million. </li>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares fell 8.97% to $1.93. The market value of their outstanding shares is at $60.2 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) shares decreased by 8.53% to $0.33. The company's market cap stands at $10.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares fell 7.31% to $8.5. The market value of their outstanding shares is at $232.3 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock declined by 6.95% to $2.41. The company's market cap stands at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

CTMX

CYCC

FORA

GNFT

LIPO

ONCO

RLMD

TVGN

YMAB

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares moved upwards by 105.9% to $9.7 during Friday's regular session. The company's market cap stands at $15.9 million. </li>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares rose 78.39% to $0.62. The company's market cap stands at $224.1 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 40.92% to $5.51. The market value of their outstanding shares is at $113.0 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock rose 29.3% to $0.56. The market value of their outstanding shares is at $14.0 million. As per the press release, Q4 earnings came out today. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares moved upwards by 14.24% to $0.88. The market value of their outstanding shares is at $23.5 million. </li>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares increased by 14.09% to $0.78. The company's market cap stands at $42.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 72.5% to $0.04 during Friday's regular session. </li>
<li>Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares declined by 60.37% to $0.89. The market value of their outstanding shares is at $47.5 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares fell 51.28% to $0.02. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 29.73% to $1.6. The company's market cap stands at $18.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined by 27.68% to $2.64. The company's market cap stands at $1.7 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock fell 26.02% to $25.8. The market value of their outstanding shares is at $335.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LGMK

LXRX

MIST

PRLD

PRTG

SNSE

STSS

12 Health Care Stocks Moving In Friday's Intraday Session

DBV Technologies SA &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>), a clinical-stage biopharmaceutical company focused on pediatric allergies, <a href="https://www.benzinga.com/pressreleases/25/03/g44528665/dbv-technologies-announces-financing-of-up-to-306-9-million-284-5-million-to-advance-viaskin-peanu">announced a financing deal</a> of up to $306.9 million (€284.5 million). The stock is up some 50% to $5.90 during Friday&#8217;s session following the deal.
What To Know: The company will receive $125.5 million (€116.3 million) upon closing, with an additional $181.4 million (€168.2 million) possible if all warrants are exercised.
The funding will support working capital, the Viaskin Peanut program, a potential Biologics License Application, and a U.S. launch if approved. The financing, led by major healthcare investors, could dilute existing shareholders by up to 73.7%. 
CEO Daniel Tassé highlighted the company's alignment with the FDA on safety data, potentially expediting the BLA submission. The Phase 3 VITESSE study, exceeding enrollment expectations, aims for results in fourth-quarter 2025.
Read Also: <a href="https://www.benzinga.com/news/25/03/44539023/whats-going-on-with-ford-stock-2">What&#8217;s Going On With Ford Stock?</a>
<h2 class="wp-block-heading">How To Buy DBVT Stock</h2>
By now you're likely curious about how to participate in the market for DBV Technologies &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, DBVT has a 52-week high of $8.32 and a 52-week low of $2.20.

Why DBV Technologies (DBVT) Stock Is Skyrocketing

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 500 points on Friday.
The Dow traded down 1.21% to 41,788.66 while the NASDAQ fell 2.11% to 17,424.77. The S&amp;P 500 also fell, dropping, 1.49% to 5,608.74.
Check This Out: <a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a>
Leading and Lagging Sectors Utilities shares jumped by 1.2% on Friday.
In trading on Friday, consumer discretionary shares fell by 2.8%.
Top Headline
The Federal Reserve&#8217;s preferred inflation gauge rose more than anticipated in February, underscoring the bumpy road back to the 2% target and throwing cold water on expectations for imminent interest rate cuts.
According to data released Friday by the Bureau of Economic Analysis, the Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares shot up 126% to $10.67 after the company reported new data for PORT-7 at the 2025 European Lung Cancer Congress.</li>
<li>Shares of Abacus Global Management, Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NYSE">ABL</a>)got a boost, surging 13% to $8.11 following strong quarterly sales.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares were also up, gaining 48% to $6.00 after the company announced up to $307 million in financing to advance the Viaskin Peanut program.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Milestone Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares dropped 62% to $0.8550 after the company received a letter from the FDA for its new drug application for CARDAMYST nasal spray.</li>
<li>Shares of XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) were down 48% to $1.29 after the company priced its public offering at $1.36 per share.</li>
<li>AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) was down, falling 16% to $57.37 after the company reported a third-quarter sales miss.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $69.76 while gold traded up 0.7% at $3,112.20.
Silver traded up 0.7% to $35.340 on Friday, while copper rose 0.7% to $5.1545.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 declined 0.3%, Germany's DAX 40 fell 0.5% and France's CAC 40 declined 0.6%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 rose 0.1%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 1.80%, China's Shanghai Composite Index declining 0.67%, Hong Kong's Hang Seng Index dipping 0.65% and India's BSE Sensex falling 0.25%.
Economics
<ul>
<li>The Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.</li>
<li>Personal spending rose 0.4% month-over-month in February after a 0.3% contraction in January, but missing expectations for a 0.5% increase.</li>
<li>Personal income growth accelerated to 0.8%, above January&#8217;s 0.7% and well beyond the 0.4% estimate. </li>
<li>The University of Michigan consumer sentiment fell to 57 in March versus a preliminary reading of 57.9.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44534992/how-to-earn-500-a-month-from-pvh-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PVH Stock Ahead Of Q4 Earnings</a></li>
</ul>
Photo: Shutterstock

Equities

Eurozone

Commodities

Intraday Update

XTIA

Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher

U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Friday.
Following the market opening Friday, the Dow traded down 0.24% to 42,198.64 while the NASDAQ fell 0.57% to 17,701.94. The S&amp;P 500 also fell, dropping, 0.36% to 5,672.68.
Check This Out: <a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a>
Leading and Lagging Sectors Utilities shares jumped by 0.6% on Friday.
In trading on Friday, consumer discretionary shares fell by 1.4%.
Top Headline
The Federal Reserve&#8217;s preferred inflation gauge rose more than anticipated in February, underscoring the bumpy road back to the 2% target and throwing cold water on expectations for imminent interest rate cuts.
According to data released Friday by the Bureau of Economic Analysis, the Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares shot up 170% to $12.79 after the company reported new data for PORT-7 at the 2025 European Lung Cancer Congress.</li>
<li>Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>)got a boost, surging 83% to $0.6359 after the company announced an exclusive license agreement with Novo Nordisk for LX9851.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares were also up, gaining 43% to $5.79 after the company announced up to $307 million in financing to advance the Viaskin Peanut program.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Milestone Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares dropped 64% to $0.7997 after the company received a letter from the FDA for its new drug applicationfFor CARDAMYST nasal spray.</li>
<li>Shares of XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) were down 48% to $1.2689 after the company priced its public offering at $1.36 per share.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) was down, falling 41% to $3.18. On Thursday, Wolfspeed announced the appointment of Robert Feurle as CEO, effective May 1, 2025.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $69.82 while gold traded up 0.5% at $3,106.80.
Silver traded up 0.5% to $35.255 on Friday, while copper rose 0.5% to $5.1440.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 declined 0.3%, Germany's DAX 40 fell 0.5% and France's CAC 40 dipped 0.6%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 rose 0.1%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 1.80%, China's Shanghai Composite Index declining 0.67%, Hong Kong's Hang Seng Index dipping 0.65% and India's BSE Sensex falling 0.25%.
Economics
<ul>
<li>The Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.</li>
<li>Personal spending rose 0.4% month-over-month in February after a 0.3% contraction in January, but missing expectations for a 0.5% increase.</li>
<li>Personal income growth accelerated to 0.8%, above January&#8217;s 0.7% and well beyond the 0.4% estimate.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44534992/how-to-earn-500-a-month-from-pvh-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PVH Stock Ahead Of Q4 Earnings</a></li>
</ul>
Photo: Shutterstock

WOLF

Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected

Press Releases

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

DBV Technologies Reports First Quarter 2025 Financial Results

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

Information regarding the total number of voting rights and   total number of shares of the Company as of April 30, 2025

Combined General Meeting of June 11, 2025

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

DBV Technologies to Participate in Upcoming EAACI Congress 2025

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

Comments

DBV Technologies

Noticias

Últimas noticias sobre DBV Technologies (NASDAQ:DBVT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL